Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.60 |
| ▸ | AR | P10275 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8706199 | 0.82 | MAOB (0.67) | MAOBCYP19A1ARHSD17B10KDM4E | |
| SCHEMBL9711662 | 0.81 | MAOB (0.56) | MAOBCYP19A1ARHSD17B10KDM4E | |
| SCHEMBL8396111 | 0.79 | MAOB (0.53) | MAOBCYP19A1ARHSD17B10KDM4E | |
| SCHEMBL11060770 | 0.78 | CYP19A1 (0.45) | MAOBCYP19A1ARHSD17B10KDM4E | |
| SCHEMBL11060773 | 0.78 | CYP19A1 (0.45) | MAOBCYP19A1ARHSD17B10KDM4E | |
| SCHEMBL9405189 | 0.76 | TSHR (0.52) | MAOBCYP19A1ARHSD17B10KDM4E | |
| SCHEMBL9012682 | 0.76 | TSHR (0.46) | MAOBCYP19A1ARHSD17B10KDM4E | |
| SCHEMBL21553352 | 0.76 | CYP2C19 (0.80) | MAOBCYP19A1ARHSD17B10KDM4E | |
| SCHEMBL982856 | 0.76 | TSHR (0.46) | MAOBCYP19A1ARHSD17B10KDM4E | |
| SCHEMBL7339250 | 0.76 | TSHR (0.46) | MAOBCYP19A1ARHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3429567-B1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY AND/OR DIABETES AND FOR IDENTIFYING CANDIDATE TREATMENT AGENTS | THE J DAVID GLADSTONE INST (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023003890-A1 | METHODS FOR BETA-LACTONE COPOLYMERIZATION | NOVOMER, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022182810-A1 | METHODS FOR PRODUCTION OF BIODEGRADABLE POLYESTERS | NOVOMER, INC. (US) | 2022-09-01 | — | — | WO | disclosed |
| US-20220257576-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY AND/OR DIABETES AND FOR IDENTIFYING CANDIDATE TREATMENT AGENTS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2022-08-18 | — | — | US | disclosed |
| US-11376242-B2 | Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents | THE J. DAVID GLADSTONE INSTITUTES (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210221762-A1 | SYSTEMS AND PROCESSES FOR PRODUCING ORGANIC ACIDS DIRECTLY FROM BETA-LACTONES | NOVOMER, INC. | 2021-07-22 | — | — | US | disclosed |
| US-10961209-B2 | Processes for producing beta-lactone and beta-lactone derivatives with heterogenous catalysts | NOVOMER, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| CN-109414414-A | Method and composition for treating obesity and/or diabetes and for identifying candidate therapeutic agent | 戴维·格拉德斯通研究所 | 2019-03-01 | — | — | CN | disclosed |
| US-20190047972-A1 | PROCESSES FOR PRODUCING BETA-LACTONE AND BETA-LACTONE DERIVATIVES WITH HETEROGENOUS CATALYSTS | NOVOMER, INC. (US) | 2019-02-14 | — | — | US | disclosed |
| EP-3429567-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY AND/OR DIABETES AND FOR IDENTIFYING CANDIDATE TREATMENT AGENTS | The J. David Gladstone Institutes (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20040206633-A1 | oxidation of aromatic hydrocarbons into cyclopentanone compound; oxidation of fluorene into polyfluorenone | IM&T RESEARCH, INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040210033-A1 | Electrochemistry polymerization; blend of aromatic resin and cyclopentanone ; oxidation to polyfluorenes | IM&T RESEARCH, INC. | 2004-10-21 | — | — | US | disclosed |
| US-6767446-B2 | ELECTROLYTIC POLYMERIZATION OF AROMATIC HYDROCARBONS SUCH AS FLUORENE IN THE PRESENCE OF AN ESTER; OXIDIZING RESULTING POLYMER TO PRODUCE A CYCLOPENTANONE-CONTAINING POLYMER SUCH AS POLY(9-FLUORENONE); LIGHT EMITTING DIODES | IM&T RESEARCH, INC. | 2004-07-27 | — | — | US | disclosed |
| CN-1128819-C | Water soluble polymers and their use in cosmetic formulations | BASF AG (DE) | 2003-11-26 | — | — | CN | disclosed |
| US-20030081432-A1 | Electrolytic polymerization of aromatic hydrocarbons such as fluorene in the presence of an ester; oxidizing resulting polymer to produce a cyclopentanone-containing polymer such as poly(9-fluorenone); light emitting diodes | IM&T RESEARCH, INC. | 2003-05-01 | — | — | US | disclosed |
| US-20030066757-A1 | Method for preparing polymers containing cyclopentanone structures | IM&T RESEARCH, INC. | 2003-04-10 | — | — | US | disclosed |
| US-6458348-B1 | Use of water-soluble polymers as biocides | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-01 | — | — | US | disclosed |
| EP-0915915-B1 | WATER SOLUBLE POLYMERS AND THEIR USE IN COSMETIC FORMULATIONS | BASF AG (DE) | 2001-10-31 | — | — | EP | disclosed |
| US-6271327-B1 | HYDROXYALKYLACRYLIC AMIDES AND DIHYDROXYALKYLACRYLIC IMIDE POLYMERS | BASF AKTIENGESELLSCHAFT (DE) | 2001-08-07 | — | — | US | disclosed |
| CN-1232473-A | Water-soluble polymers and their use in cosmetic formulations | BASF AG (DE) | 1999-10-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376242-B2 | Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents | PNLIP, LIPC, IAPP | MAOB 4303/4885CYP19A1 3267/4885AR 4826/4885 |
| US-10961209-B2 | Processes for producing beta-lactone and beta-lactone derivatives with heterogenous catalysts | AGL, HBZ, RIOX2 | MAOB 881/4885CYP19A1 564/4885AR 3882/4885 |
| US-20220257576-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY AND/OR DIABETES AND FOR IDENTIFYING CANDIDATE TREATMENT AGENTS | PNLIP, LIPC, IAPP | MAOB 4303/4885CYP19A1 3267/4885AR 4826/4885 |
| US-20190047972-A1 | PROCESSES FOR PRODUCING BETA-LACTONE AND BETA-LACTONE DERIVATIVES WITH HETEROGENOUS CATALYSTS | AGL, HBZ, RIOX2 | MAOB 881/4885CYP19A1 564/4885AR 3882/4885 |
| US-20210221762-A1 | SYSTEMS AND PROCESSES FOR PRODUCING ORGANIC ACIDS DIRECTLY FROM BETA-LACTONES | AGL, FGB, COASY | MAOB 772/4885CYP19A1 300/4885AR 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.